Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Deficit - USD ($) $ in Thousands	Total	Series A-1 Convertible Preferred Stock	Series A-2 Convertible Preferred Stock	Series B Convertible Preferred Stock	Class A Common Stock	Class B Common Stock	Preferred Stock	Common Stock	Common Stock Conversion of convertible preferred stock into common stock and pre-funded warrants in connection with the reverse merger	Common Stock Conversion of Class A common stock into common stock and related change in par value	Common Stock Class A Common Stock	Common Stock Class A Common Stock Conversion of Class A common stock into common stock and related change in par value	Common Stock Class B Common Stock	Additional Paid- In Capital	Additional Paid- In Capital Conversion of convertible preferred stock into common stock and pre-funded warrants in connection with the reverse merger	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022		18,604,653	13,291,208	74,405,719
Beginning balance at Dec. 31, 2022		$ 34,414	$ 28,675	$ 181,277
Increase (Decrease) in Temporary Equity [Roll Forward]
Additional convertible preferred stock issued in conjunction with anti-dilution adjustment (in shares)		1,890,302	1,350,436	10,264,533
Conversion of convertible preferred stock into common stock and pre-funded warrants in connection with the reverse merger (in shares)		(20,494,955)	(14,641,644)	(84,670,252)
Conversion of convertible preferred stock into common stock and pre-funded warrants in connection with the reverse merger		$ (34,414)	$ (28,675)	$ (181,277)
Ending balance at Dec. 31, 2023		$ 0	$ 0	$ 0
Ending balance (in shares) at Dec. 31, 2023		0	0	0
Beginning balance (in shares) at Dec. 31, 2022							0
Beginning balance (in shares) at Dec. 31, 2022								0			428,334		0
Beginning balance at Dec. 31, 2022	$ (145,739)						$ 0	$ 0			$ 0		$ 0	$ 5,098		$ (150,837)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Class A common stock issued upon exercise of stock options														1,418
Class A common stock issued upon exercise of stock options (in shares)											20,348
Class A common stock issued upon exercise of stock options	168													168
Conversion of convertible preferred stock into common stock and pre-funded warrants in connection with the reverse merger (in shares)									7,231,747	3,240,888		(3,240,888)
Conversion of convertible preferred stock into common stock and pre-funded warrants in connection with the reverse merger	244,366														$ 244,366
Issuance of Class A common stock and pre-funded warrants in the pre-closing financing, net of $6,946 offering costs (in shares)											2,792,206
Issuance of Class A common stock and pre-funded warrants in the pre-closing financing, net of $6,946 offering costs	88,056													88,056
Transactions costs associated with the reverse merger	(4,140)													(4,140)
Issuance of common stock and pre-funded warrants to former stockholders of Neoleukin Therapeutics, Inc. in connection with the reverse merger (in shares)								2,351,030
Issuance of common stock and pre-funded warrants to former stockholders of Neoleukin Therapeutics, Inc. in connection with the reverse merger	38,212													38,212
Net loss	(36,317)															(36,317)
Ending balance at Dec. 31, 2023	$ 186,024						$ 0	$ 0			$ 0		$ 0	373,178		(187,154)
Ending balance (in shares) at Dec. 31, 2023	12,823,665							12,823,665			0		0
Ending balance (in shares) at Dec. 31, 2023	0						0
Beginning balance (in shares) at Dec. 31, 2022		18,604,653	13,291,208	74,405,719
Beginning balance at Dec. 31, 2022		$ 34,414	$ 28,675	$ 181,277
Beginning balance (in shares) at Dec. 31, 2022							0
Beginning balance (in shares) at Dec. 31, 2022								0			428,334		0
Beginning balance at Dec. 31, 2022	$ (145,739)						$ 0	$ 0			$ 0		$ 0	5,098		(150,837)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss					$ (49,971)	$ 0
Ending balance (in shares) at Dec. 18, 2023					12,823,665
Ending balance at Dec. 31, 2023		$ 0	$ 0	$ 0
Ending balance (in shares) at Dec. 31, 2023		0	0	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	13,654
Ending balance at Dec. 31, 2023	$ 186,024						$ 0	$ 0			$ 0		$ 0	373,178		(187,154)
Ending balance (in shares) at Dec. 31, 2023	12,823,665							12,823,665			0		0
Ending balance (in shares) at Dec. 31, 2023	0						0
Ending balance at Dec. 31, 2024		$ 0	$ 0	$ 0
Ending balance (in shares) at Dec. 31, 2024		0	0	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Class A common stock issued upon exercise of stock options														8,320
Class A common stock issued upon exercise of stock options (in shares)	92,653							92,653
Class A common stock issued upon exercise of stock options	$ 1,676													1,676
Issuance of Class A common stock and pre-funded warrants in the pre-closing financing, net of $6,946 offering costs (in shares)								1,835,000
Issuance of Class A common stock and pre-funded warrants in the pre-closing financing, net of $6,946 offering costs	189,499													189,499
Shares issued upon the exercise of pre-funded warrants (in shares)								103,407
Net loss	(75,144)															(75,144)
Ending balance at Dec. 31, 2024	$ 310,375						$ 0	$ 0			$ 0		$ 0	$ 572,673		$ (262,298)
Ending balance (in shares) at Dec. 31, 2024	14,854,725							14,854,725			0		0
Ending balance (in shares) at Dec. 31, 2024	0						0